Accessibility Menu
Taysha Gene Therapies logo

Taysha Gene Therapies(NASDAQ) TSHA

Current Price$5.55
Market Cap$1.86BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-76%
5 Year-69%
1 Year+117%
1 Month-15%
Taysha Gene Therapies last closing stock price
MetricPriceDate
Last closeUSD 5.832026-07-23
Taysha Gene Therapies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.35%USD 5.972026-07-16
1 month-15.01%USD 6.862026-06-23
3 month-8.91%USD 6.402026-04-24
Year to date+6%USD 5.502025-12-31
1 year+116.73%USD 2.692025-07-23
3 year+770.41%USD 0.672023-07-24
5 year-68.87%USD 18.732021-07-23
Since inception-75.77%USD 24.062020-09-24

Taysha Gene Therapies Financials at a Glance

Market Cap

$1.86BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$7.47M

Net Income (TTM)

-$129.88M

EPS (TTM)

-$0.40

P/E Ratio

-14.71

Dividend

$0.00

Beta (Volatility)

1.79 (High)

Price

$5.55

Volume

229,795.035

Open

$5.89

Previous Close

$5.83

Daily Range

$5.48 - $5.95

52-Week Range

$2.53 - $7.30

Estimated Earnings Date

Aug 11, 2026

TSHA News

SellAlert-Red.png

Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run

Jonathan PoncianoJul 12, 2026

TSHA: Motley Fool Moneyball Superscore

55

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Taysha Gene Therapies

Taysha makes medicine for children with rare brain disorders. These treatments fix the single gene that causes the disease. This helps patients who currently have no other treatment options.

Fixing Genes at the Source

  • TSHA-102: Gene therapy for Rett syndrome delivered by injection into the spinal fluid; currently in pivotal clinical trials.
  • TSHA-113: Treatment for neurodegenerative diseases involving specific protein tangles in the brain, such as Alzheimer's.
  • TSHA-114: Therapy for Fragile X syndrome, which is the most common single-gene cause of autism.
  • Viral Platform: Delivery system using adeno-associated virus 9, or AAV9, to transport healthy genetic material to the central nervous system.

Strategic Shifts and Milestones

  • Regained full global rights to TSHA-102 in October 2025 after an option agreement with Astellas Gene Therapy expired.
  • Finalized alignment with the Food and Drug Administration in 2025 on a six-month interim analysis for its drug application.
  • Terminated a license agreement for Batten disease treatments with Abeona Therapeutics Inc. in February 2026.
  • Completed patient enrollment for two separate clinical trials evaluating TSHA-102 in pediatric and adult female patients.

How Precision Controls Safety

The company uses a unique technology called miRARE to regulate medicine levels in each cell, which prevents the risks of over-treatment. It maintains a deep partnership with the University of Texas Southwestern Medical Center to discover and develop new therapies.

The 2025 Scorecard

  • Revenue reached $5.5 million in Q4 2025, up 171.3% from the prior year.
  • Net income was -$27.9 million in Q4 2025, which worsened from -$18.8 million in Q4 2024.
  • Market capitalization hit $1.5 billion in Q4 2025, a 396% increase year-over-year.
  • Operating cash flow was -$26.7 million in Q4 2025, which worsened 46% compared to Q4 2024.

A Clearer Focus

Taysha has evolved into a clinical-stage developer with a narrowed focus on its lead candidate for Rett syndrome. Its strategy relies on advanced gene-control technology and regaining global rights to its most promising assets.

AI Generated • Apr 29, 2026

Industry

Biotechnology

Sector

Health Care

Employees

99

CEO

Sean P. Nolan

Website

www.tayshagtx.com

Headquarters

Dallas, TX 75247, US

TSHA Financials

Key Financial Metrics (TTM)

Gross Margin

88.22%

Operating Margin

-1774.37%

Net Income Margin

-1738.40%

Return on Equity

-56.07%

Return on Capital

-41.68%

Return on Assets

-43.24%

Earnings Yield

-6.80%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.86BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

319.86M

Volume

229.80K

Avg. Volume

3.02M

Financials (TTM)

Gross Profit

$6.59M

Operating Income

-$132.56M

EBITDA

-$129.13M

Operating Cash Flow

-$111.95M

Capital Expenditure

-$3.38M

Free Cash Flow

-$115.33M

Cash & ST Invst.

$276.58M

Total Debt

$17.77M

Taysha Gene Therapies Performance Analysis

Taysha Gene Therapies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,502,000N/A
20232023-12-31USD 15,451,000517.5%
20242024-12-31USD 8,333,000-46.1%
20252025-12-31USD 9,773,00017.3%
Taysha Gene Therapies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-13.7%
Q32025-09-30-100.0%
Q42025-12-31N/A
Q12026-03-31-100.0%
Taysha Gene Therapies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -3.78-18.5%
20232023-12-31USD -0.96-74.6%
20242024-12-31USD -0.36-62.8%
20252025-12-31USD -0.34-4.5%
Taysha Gene Therapies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-12.9%
Q32025-09-30-2.7%
Q42025-12-3113.6%
Q12026-03-31-50.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$295.00K

-112.8%

Gross Margin

0.00%

N/A

Market Cap

$1.86BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$18.84M

N/A

Employees

99

N/A

Net Income

-$42.41M

-97.0%

EBITDA

-$42.11M

-98.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$276.58M

+137.2%

Total Debt

$17.77M

-71.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$17.77M

-70.2%

Short Term Debt

$0.00

-100.0%

Return on Assets

-43.24%

N/A

Return on Invested Capital

-47.30%

N/A

Free Cash Flow

-$43.90M

-96.0%

Operating Cash Flow

-$40.88M

-85.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
XNCRXencor, Inc.
$19.36-0.87%
ANABAnaptysBio, Inc.
$54.20-1.30%
NKTRNektar Therapeutics
$71.07+2.47%
IMTXImmatics N.V.
$9.16-1.45%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.30-0.06%
TQQQProShares Trust - ProShares UltraPro Qqq
$64.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$44.16+0.02%
CLFCleveland-Cliffs
$11.05+0.01%

Questions About TSHA

What is the current price of Taysha Gene Therapies?

Taysha Gene Therapies is trading at $5.51 per share.

What is the 52-week range for Taysha Gene Therapies?

Over the past 52 weeks, Taysha Gene Therapies has traded between $2.53 and $7.30.

How much debt does Taysha Gene Therapies have?

As of the most recent reporting period, Taysha Gene Therapies reported total debt of $68.83M.

How much cash does Taysha Gene Therapies have on hand?

Taysha Gene Therapies reported $277.03M in cash and cash equivalents in its most recent financial results.

What is Taysha Gene Therapies’s dividend yield?

Taysha Gene Therapies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services